Regeneron Genetics Center
New ultra high-throughput DNA sequencing technology is making it economically feasible to sequence the DNA of tens of thousands of individuals, while health systems and investigators around the world have developed impressive resources for genetics discovery research including large-scale biobanks and sophisticated methods of analyzing health-related data. We believe the time is right to apply energy and novel methods to mine patient-consented sets of molecular and clinical information for medically-relevant associations.
The Regeneron Genetics Center, announced in January 2014, builds upon Regeneron's strengths in mouse genetics (VelociGene®; VelocImmune® and related technologies) and genetics-driven drug discovery and development (e.g. ARCALYST® (rilonacept) Injection, our Interleukin-1 blocker; alirocumab, our fully human antibody to the LDL cholesterol-regulating target PCSK9; and several other important pipeline medicines).
Our objective is to elucidate, on a large scale, genetic factors that cause or influence a range of human diseases. We believe that the knowledge we and our collaborators create can advance basic science around the world, provide clinically-valuable insights to physicians and patients, and identify novel targets for drug development.
Specific activities being scaled up will include gene sequencing projects, functional biology and mouse genetics for disease modeling, and translational research integrating genetics discovery research with the growing Regeneron pipeline. Program goals include target discovery, indication discovery, and patient-disease stratification through the use of human genetics and related genomic sciences. Our interests encompass a breadth of different areas such as Mendelian and family frameworks, large scale population genetics (both common and rare variants), and gene-gene interactions.
Scientific Advisory Board
The Regeneron Genetics Center Scientific Advisory Board is chaired by Richard Lifton, M.D., Ph.D., the Sterling Professor of Genetics, Professor of Medicine (Nephrology), and Chairman of the Department of Genetics at Yale University and an investigator at the Howard Hughes Medical Institute. In addition to Dr. Lifton, the RGC scientific advisory board consists of seven prominent members of the genetics research community:
- Goncalo Abecasis, Ph.D., Chairman of the Department of Biostatistics and Felix E. Moore Collegiate Professor of Biostatistics at the University of Michigan;
- Wendy Chung, M.D., Ph.D., Herbert Irving Associate Professor of Pediatrics at the Columbia University Medical Center;
- Peter Donnelly, Ph.D., Professor of Statistical Science and Director of the Wellcome Trust Centre for Human Genetics;
- Tim Hunkapiller, Ph.D., President of Discovery Biosciences Corporation;
- Sekar Kathiresan, M.D., Director of Preventive Cardiology at Massachusetts General Hospital, Associate Member in the Broad Institute’s Program in Medical and Population Genetics, and Associate Professor of Medicine at Harvard Medical School;
- James R. Lupski, M.D., Ph.D., D.Sc.(hon), Cullen Professor Molecular and Human Genetics at the Baylor College of Medicine; and
- Elaine Mardis, Ph.D., Robert E. and Louise F. Dunn Distinguished Professor of Medicine and Co-Director at the Genome Institute at the Washington University School of Medicine.
Alan Shuldiner, M.D.
Vice President, Translational Genetics
Aris Baras, M.D.
Executive Director, Regeneron Genetics Center
Rick Dewey, M.D.
Director, Translational Genetics
John Overton, Ph.D.
Director, Sequencing and Lab Operations
Jeffrey Reid, Ph.D.
Senior Director, Genome Informatics
Regeneron Genetics Center Founders and Regeneron Genetics Steering Committee
George Yancopoulos, M.D., Ph.D.
Aris Baras, M.D.
Aris Economides, Ph.D.
Scott Mellis, M.D., Ph.D.
Andrew Murphy, Ph.D.
Robert Phillips, Ph.D.
Neil Stahl, Ph.D.